• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Beaver-Visitec to purchase Endo Optiks

Article

Beaver-Visitec has announced the purchase of Endo Optiks, a company that focuses on the treatment of glaucoma and retinal diseases via minimally invasive endoscopy.

Waltham, MA-Beaver-Visitec has announced the purchase of Endo Optiks, a company that focuses on the treatment of glaucoma and retinal diseases via minimally invasive endoscopy.

More in this issue: New parameter aims to improve visual field sensitivity testing

The Endo Optiks system enables visualization of eye anatomy that could not otherwise be viewed, and involves novel treatment approaches supported by a significant body of clinical evidence.

Beaver-Visitec is a portfolio company of RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the health-care industry.

"We are excited to bring the Endo Optiks technology and products to our customers as a part of the Beaver-Visitec offerings,” said Tom Kapfer, president and chief executive officer of Beaver-Visitec.

“The addition of Endo Optiks technology to (our) portfolio furthers our commitment to providing high-quality, innovative solutions that improve safety and provide better outcomes for surgeons and patients," he continued.

Financial terms of the transaction were not disclosed.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.